Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
editorial
. 1991 Apr;65(4):175–176. doi: 10.1136/hrt.65.4.175

Coronary thrombolysis: round two and beyond

Editor: R G Wilcox1
PMCID: PMC1024598  PMID: 1903042

Full text

PDF
175

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bentley P. G., Kakkar V. V., Scully M. F., MacGregor I. R., Webb P., Chan P., Jones N. An objective study of alternative methods of heparin administration. Thromb Res. 1980 Apr 1;18(1-2):177–187. doi: 10.1016/0049-3848(80)90182-6. [DOI] [PubMed] [Google Scholar]
  2. Hsia J., Hamilton W. P., Kleiman N., Roberts R., Chaitman B. R., Ross A. M. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med. 1990 Nov 22;323(21):1433–1437. doi: 10.1056/NEJM199011223232101. [DOI] [PubMed] [Google Scholar]
  3. Hull R. D., Raskob G. E., Hirsh J., Jay R. M., Leclerc J. R., Geerts W. H., Rosenbloom D., Sackett D. L., Anderson C., Harrison L. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986 Oct 30;315(18):1109–1114. doi: 10.1056/NEJM198610303151801. [DOI] [PubMed] [Google Scholar]
  4. Jalihal S., Morris G. K. Antistreptokinase titres after intravenous streptokinase. Lancet. 1990 Jan 27;335(8683):184–185. doi: 10.1016/0140-6736(90)90276-b. [DOI] [PubMed] [Google Scholar]
  5. Neuhaus K. L., Feuerer W., Jeep-Tebbe S., Niederer W., Vogt A., Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1989 Nov 15;14(6):1566–1569. doi: 10.1016/0735-1097(89)90399-9. [DOI] [PubMed] [Google Scholar]
  6. Rapold H. J. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet. 1990 Feb 24;335(8687):481–482. doi: 10.1016/0140-6736(90)90720-p. [DOI] [PubMed] [Google Scholar]
  7. Topol E. J., George B. S., Kereiakes D. J., Stump D. C., Candela R. J., Abbottsmith C. W., Aronson L., Pickel A., Boswick J. M., Lee K. L. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation. 1989 Feb;79(2):281–286. doi: 10.1161/01.cir.79.2.281. [DOI] [PubMed] [Google Scholar]
  8. Verstraete M., Bernard R., Bory M., Brower R. W., Collen D., de Bono D. P., Erbel R., Huhmann W., Lennane R. J., Lubsen J. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet. 1985 Apr 13;1(8433):842–847. doi: 10.1016/s0140-6736(85)92208-1. [DOI] [PubMed] [Google Scholar]
  9. Wilcox R. G., von der Lippe G., Olsson C. G., Jensen G., Skene A. M., Hampton J. R. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis. Lancet. 1990 May 19;335(8699):1175–1178. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES